Lowest Price Guaranteed
Pages
972
Last Updated
June 2026
View Count
40675
The global gene therapy market, valued at USD 4.20 billion in 2025, is projected to reach USD 6.07 billion in 2026 and USD 20.47 billion by 2035, with a 14.5% CAGR during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
The new research study consists of industry trends, detailed gene therapy market analysis, key market insights, market impact analysis, and demand analysis. In addition, the report includes information related to the market forecast of gene therapies along with their sales forecast. The sales forecast includes the marketed and clinical-stage (phase III) gene therapies.
Health disorders arising from congenital abnormalities and inherited genetic mutations have a profound impact on individuals throughout their lives. These chronic conditions encompass a diverse range of disorders, including autoimmune disorders, genetic disorders, neurological disorders and oncological disorders. Such disorders arise from inherited genetic anomalies that disrupt the normal functioning of genes and adversely affect the protein encoding process. According to the World Health Organization (WHO), 10 out of every 1,000 individuals are affected by genetic disorders, with over 70 million people worldwide living with such conditions. In fact, more than 40% of infant mortality globally is associated with various genetic disorders. Therefore, in order to address the aforementioned challenges, several research initiatives are underway to develop effective methods for delivering targeted therapies directly to affected organs or cells. In this regard, gene therapies have emerged as a revolutionary approach and have proven to be a promising modality in treating wide array of diseases.
Gene therapies aim to address the underlying genetic cause of a disease by either introducing a healthy version of the mutated gene or by inactivating the faulty / disease-causing genes in of the body. It is worth mentioning that in 2003, Gendicine® (Sibiono GeneTech) became the world’s first gene therapy to receive regulatory approval from the China FDA. Since then, in the past two decades, there have been several breakthroughs related to the development of gene therapies. For instance, in December 2017, the USFDA approved Luxturna® (Spark Therapeutics), the first gene therapy intended for the treatment of inherited retinal disorders. Additionally, in May 2019, the USFDA approved ZOLGENSMA® (Novartis), the first gene therapy for the treatment of spinal muscular atrophy in pediatric patients. It is worth highlighting that the therapy received multiple designations, namely breakthrough therapy, fast track, orphan drug and priority review designations which resulted in the expedited approval of the drug in the US. Further, in 2023, five gene therapies received the USFDA market approval for various therapeutic indications.
Additionally, in April 2024, more than 1,100 active clinical trials are evaluating gene therapies across various phases of clinical studies. In fact, three gene therapies have already received regulatory approval in 2024, and according to predictions made by USFDA in 2019, 10 to 20 therapies are expected to gain market access, each year, till 2025. It is worth highlighting that the promising results from ongoing clinical research initiatives have spurred investments from both government and private sectors to support the development of these therapeutic products. Taking into consideration the continuous investments and progress in this domain, gene therapies are anticipated to be utilized for the treatment of more than 65.6 million patients suffering from a myriad of disease indications, by 2034.
With the rapidly evolving gene therapy product portfolio, an increasing number of startups and big pharma players are entering the gene therapy market. Presently, 345 gene therapy companies are engaged in developing various early and late-stage therapies worldwide. Further, in recent years, there has been a significant increase in the integration of novel technologies, such as gene modification, genome editing, genome sequencing and manipulation technologies (molecular / gene switch), in conjugation with advanced gene delivery methods. Moreover, next-generation delivery platforms, including nanoparticles and hybrid vector systems, have demonstrated the capability to facilitate effective, precise and safe delivery of gene-based therapeutics, thereby enabling more targeted treatment approaches. Driven by the collective efforts of gene therapy companies coupled with advancements in technology and growing preference for single-dose effective therapeutics, the gene therapy market is poised to witness substantial market growth during the forecast period.
 |
 |
 |
The market report presents an in-depth analysis of the various gene therapy companies in this domain, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2018 | |
| Forecast Period | Till 2035 | |
| Market Size by 2026 | USD 6.07 billion | |
| CAGR (Till 2035) | 14.5% | |
| Therapeutic Area |
|
|
| Type of Vector |
|
|
| Type of Therapy |
|
|
| Type of Gene Delivery Method |
|
|
| Route of Administration |
|
|
| Geographical Regions |
|
|
| Leading Players |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
 |
 |
 |
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of gene therapies, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035.
The market report also features the likely distribution of the current and forecasted opportunity across various segments, such as therapeutic area (cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle disorders, oncological disorders, ophthalmic disorders and other disorders), type of vector (adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, lentivirus vectors, non-viral vectors, retrovirus vectors and other viral vectors), type of therapy (gene augmentation, gene editing, gene regulation, oncolytic immunotherapies and other therapies), type of gene delivery method (ex vivo gene delivery and in vivo gene delivery), route of administration (intramuscular route, intratumoral route, intravenous route, subretinal route and other routes of administration), geographical regions (North America, Europe, Asia-Pacific, Latin America and Rest of the World), leading players and sales forecast.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three gene therapy market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by the discussions conducted with multiple stakeholders in the gene therapy market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders:
Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on therapeutic area, the global market for gene therapies is segmented across cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle disorders, oncological diseases, ophthalmic disorders and other disorders. Currently, muscle disorders segment occupies the highest gene therapy market share (72%). This can be primarily attributed to the widespread prevalence of muscle disorders (affecting approximately 1.71 billion patients worldwide) and high efficacy of gene therapies in treating such conditions. However, in the future, hematological disorders segment is likely to capture a larger market share owing to the rising incidence of conditions, such as sickle cell disease and thalassemia, particularly in middle east countries, such as Iraq, Oman and Saudi Arabia.
Based on type of vector, the global gene therapy market is segmented into adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, lentivirus vectors, non-viral vectors, retrovirus vectors and other viral vectors. The adeno-associated virus (AAV) vector-based gene therapies currently occupy the highest share (80%) and is expected to remain dominant during the forecast period.
This can be attributed to the various advantages of AAV vector, such as high target specificity, greater efficacy and infectivity, enabling the introduction of therapeutic payloads into both dividing and non-dividing cells. Further, these vectors exhibit low immunogenicity, reducing the likelihood of triggering immune responses in patients receiving gene therapies.
Based on type of therapy, the global gene therapy market size is segmented into gene augmentation, gene editing, gene regulation, oncolytic immunotherapies and other therapies. The gene augmentation segment is anticipated to capture the largest share in the current market and this trend is unlikely to change in the foreseen future. This can be attributed to the ability of gene augmentation therapies to deliver therapeutic genes to the patient’s genome, precisely correcting the genomic mutations and potentially reducing the side effects associated with conventional treatments, thereby improving quality of life.
Based on type of gene delivery method, the global gene therapy market is segmented into ex vivo and in vivo gene delivery methods. Currently, the market in driven by in vivo gene delivery method and this trend is unlikely to change in the future. This can be primarily attributed to the fact that the in vivo approach of gene delivery is a simpler treatment process as it enables the direct delivery of genetic material to the targeted organ or cell within the patient’s body. Further, in vivo delivery method is less invasive and enhances patient accessibility by mitigating the need for complex procedures, such as cell extraction, in vitro genetic manipulation and reinfusion of modified cells, which are often associated with ex vivo delivery of gene therapies.
Based on route of administration, the global gene therapy market is segmented into intramuscular, intratumoral, intravenous, subretinal and other routes of administration. It is worth mentioning that intravenous route of administration segment is likely to capture the majority share in the current and future gene therapy market. This can be attributed to the fact that the intravenous route enables widespread distribution of the gene carrying therapeutic vector, facilitating their delivery to multiple target organs. Further, compared to other routes, such as intralesional or intratumoral, intravenous route is easier to administer and minimally invasive, which reduces the risk of complications and enhances the patient compliance to these therapies.
This segment highlights the distribution of gene therapy market value across various geographies, namely, North America, Europe, Asia-Pacific, Latin America and rest of the world. According to our projections, currently North America is likely to capture the majority share (61%) in the overall market. Further, the market for gene therapies in Europe is expected to grow at a highest CAGR of 20.93%, during the forecast period. The growth of the market in Europe can be ascribed to the rapidly growing patient population, the rising incidence rate of chronic disorders, including neurological disorders, genetic disorders and rare diseases, and the rising demand for effective and advanced therapeutics. Further, the increasing investments and initiatives taken by government authorities in the European countries to promote the adoption of gene therapies among patients and physicians is likely to drive the market in future.
The Gene Therapy Market (6th Edition): Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size and future opportunities for gene therapy companies, during the given forecast period. Further, the market report highlights the efforts of several stakeholders in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the market report are briefly discussed below.
Gene therapies market landscape features the presence of 1,313 gene therapies targeting a wide range of chronic disorders. It is worth highlighting that, more than 370 gene therapies are currently being evaluated in different phases of clinical trials, either as monotherapies or in combination with other drugs. Further, 920 gene therapies are currently in the preclinical and discovery stage of development, indicating rising need for these therapies and substantial research and development activity. Notably, in December 2023, Vertex Pharmaceuticals and CRISPR Therapeutics received approval from the USFDA for its CRISPR / Cas9 gene editing therapy, Casgevy® (Exagamglogene autotemcel) for the treatment of patients with sickle cell disease. This approval is further expanded in January 2024, to include treatment of beta-thalassemia in patients aged 12 years and above. Hence, the growing demand for novel gene therapies, regulatory approvals, and continuous advances in cell and gene therapy manufacturing process, are expected to drive the gene therapy market growth during the forecast period.
The gene therapy market landscape features the presence of 345 players, segmented across different company sizes namely, very large, large, mid-sized and small. Close to 60% of these gene therapy companies were established between 2011 and 2020, demonstrating the rising interest of industry stakeholders in the gene therapy domain.
Additionally, close to 55% of the gene therapy companies are based in North America, followed by Europe and Asia-Pacific and rest of the world. Further, within Asia-Pacific, China emerged as the hub of gene therapy developers followed by South Korea with over 20% of the companies headquartered in latter country.
Over the years, adeno-associated virus vectors have emerged as the most preferred vector for the delivery of therapeutic genes. This can be ascribed to the wide range of advantages offered by these viral vectors, such as long-term safety record, high efficiency, and low immunogenicity. Moreover, these therapies facilitate sustained gene expression, making them particularly suitable for treating chronic conditions where prolonged therapeutic effects are imperative. Notably, the USFDA has approved more than 100 investigational new drug (IND) applications to evaluate AAV-based gene therapies in various phases of clinical trials. Examples of large companies developing AAV-based gene therapies (arranged in alphabetical order) include Asklepios BioPharmaceutical, bluebird bio, Pacira BioSciences, Spark Therapeutics, Sorrento Therapeutics and Vertex Pharmaceuticals.
The demand for gene therapies is projected to reach 79,144 patients by 2035, growing at a CAGR of 11.67%. In addition, the annual commercial and annual clinical demand for gene therapies is expected to reach over 44,088 patients and 35,056 patients, respectively, by 2035. Further, in terms of therapeutic area, the current demand is driven by gene therapies developed for the treatment of oncological disorders and this trend is unlikely to change in the coming future.
Currently, the global market for gene therapies is estimated to reach USD 3.4 billion in 2025. Driven by the expanding gene therapy product portfolio, promising clinical trial results and anticipated regulatory approvals, the gene therapies market is anticipated to grow at a CAGR of 17.0% during the forecast period. The market growth is primarily fueled by the increasing population of patients with congenital abnormalities and a rising demand for gene therapies, which enhances the sales revenue generated from these therapies and subsequently contributing towards the overall gene therapy market growth.
Currently, North America is projected to capture 61% of the gene therapy market share. This can be attributed to the presence of emerging startups and several well-established big pharma companies with specialized expertise in research and development of gene therapies Additionally, the advanced healthcare infrastructure in North America enables gene therapy companies to conduct extensive clinical trials required to meet the stringent regulatory guidelines. Moreover, the gene therapies available in the region have demonstrated significant therapeutic outcomes which have enhanced the revenues generated from these drugs and has eventually expanded the market potential. Further, it is worth highlighting that the US government has been actively involved in providing reimbursement for expensive gene therapies, recognizing their potential to revolutionize healthcare and improve patient outcomes.
Examples of key gene therapy companies (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, Artgen Biotech, BioMarin Pharmaceutical, bluebird bio, CRISPR Therapeutics, CSL Behring, Ferring Pharmaceuticals, Kolon TissueGene, Krystal Biotech, Novartis, Orchard Therapeutics, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Shanghai Sunway Biotech, Sibiono GeneTech and Spark Therapeutics. This market report includes an easily searchable excel database of all the companies developing gene therapies.
The market report presents an in-depth analysis, highlighting the capabilities of various gene therapy companies, across different geographies. Amongst other elements, the market report includes:
 |
 |
 |
Several recent developments have taken place in the field of gene therapy. Some of these recent initiatives have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall gene therapy market trends that we have outlined in our analysis.